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Abstract: Since the emergence of West Nile virus (WNV) in North America in 1999, 
understanding of the clinical features, spectrum of illness and eventual functional outcomes 
of human illness has increased tremendously. Most human infections with WNV remain 
clinically silent. Among those persons developing symptomatic illness, most develop a 
self-limited febrile illness. More severe illness with WNV (West Nile neuroinvasive disease, 
WNND) is manifested as meningitis, encephalitis or an acute anterior (polio) myelitis. These 
manifestations are generally more prevalent in older persons or those with immunosuppression. 
In the future, a more thorough understanding of the long-term physical, cognitive and 
functional outcomes of persons recovering from WNV illness will be important in 
understanding the overall illness burden. 
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1. Introduction 
In the decade since the emergence of West Nile virus (WNV) in North America, our collective 
understanding of the clinical manifestations, prognostic factors and short- and long-term outcomes of 
illness has increased dramatically. Previous historic outbreaks of WNV in sub-Saharan Africa and the 
Middle East had typically been characterized as mild, self-limited febrile illness with few or no 
sequelae [1]. More recently, beginning in the 1990s, more cases of neurologic illness, particularly 
“neuroinvasive” disease, in which the virus directly infects the nervous system, began to be  
recognized [1,2]. However, the ongoing outbreak of WNV in North America has greatly expanded our 
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understanding of the spectrum of illness associated with WNV infection in humans, and a number of 
previously under-recognized syndromes have been characterized [3–6].  
It is generally estimated that about 80% of persons infected with WNV remain asymptomatic. Of 
those who develop symptoms, the vast majority develop an acute, systemic febrile illness (“West Nile 
fever”, WNF). Data suggest that less than 1% of infected persons develop neurologic illness, which is 
primarily attributed to neuroinvasive disease, in which the virus breaches the intrathecal space and 
produces infection of central nervous system (CNS) structures. Neuroinvasive disease includes aseptic 
meningitis (“West Nile meningitis”, WNM), encephalitis (“West Nile encephalitis”, WNE) or an acute 
poliomyelitis-like syndrome (“West Nile poliomyelitis”, WNP) [1,2]. WNM involves infection of the 
meninges (the outer covering of the brain and spinal cord) and makes up the largest percentage of 
neuroinvasive disease cases in younger age groups. WNE involves viral infection of the brain 
parenchyma itself and is more typically manifested in older persons or individuals with compromised 
immune systems. WNP results from viral infection of the anterior horn cells of the spinal cord, leading to 
acute flaccid limb weakness. When discussing the various manifestations of WNV infection, it is 
important to keep in mind that the clinical picture may not always be as clear-cut as delineated above, 
and sometimes, the clinical features of WNF, WNM and WNE may overlap. For example, patients may 
develop an altered mental status, due to severe systemic illness, without true histopathologic or 
radiologic evidence of cerebral inflammation or “encephalitis” in the pathophysiologic sense. Similarly, 
patients presenting with fever, headache and “neck stiffness” may not undergo lumbar puncture to 
demonstrate pleocytosis, and consequently, a diagnosis of WN “meningitis” may not be reported. Despite 
these limitations, the clinical syndrome in most persons with WNV illness can be diagnosed based 
upon clinical grounds. 
2. Clinical Syndromes Associated with WNV Infection 
2.1. West Nile Fever (WNF)  
WNF is the predominant clinical syndrome seen in most infected persons. All ages may be affected, 
but data suggest that the proportion of WNF may be higher among younger individuals [5,7–9]. 
Following an incubation period of approximately 2–14 days, infected persons typically experience the 
abrupt onset of fever, headache, fatigue and myalgias. Gastrointestinal complaints, including nausea 
and vomiting, have been frequently described and may lead to dehydration. 
WNF may sometimes be associated with a rash, which tends to be morbilliform, maculopapular and 
non-pruritic and predominates over the torso and extremities, sparing the palms and soles [10–13]. 
(Figure 1). The rash may be transient, lasting less than 24 h in some persons. Interestingly, this rash 
appears to be more frequently seen in WNF than in more severe illness manifestations (WNM or 
WNE) [10]. In addition, rash is more frequently observed among younger persons than among older 
persons [10]. These findings raise the question as to whether the presence of a rash correlates with host 
immune or cytokine response to infection. 
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Figure 1. Diffuse maculopapular rash associated with West Nile virus infection. 
 
Although elderly persons with WNF may experience adverse outcomes and have a higher mortality 
rate than younger symptomatic persons [4,8], most patients experience complete recovery. Some otherwise 
healthy persons, however, may continue to experience persistent fatigue, headaches and difficulties 
concentrating for days or weeks following infection [14]. In particular, profound fatigue, sometimes 
interfering with work or school activities, may last for months among persons recovering from WNF [15]. 
Deaths among persons with WNF occur primarily among older persons and the immunocompromised 
population and are frequently attributable to cardiopulmonary complications [16]. 
2.2. West Nile Neuroinvasive Disease  
2.2.1. West Nile Meningitis (WNM) 
WNM is essentially indistinguishable from other viral meningitides (or “aseptic meningitis”). 
Persons developing WNM experience the abrupt onset of fever and headache and demonstrate meningeal 
signs, including nuchal rigidity, Kernig’s and/or Brudzinski’s signs and photophobia or phonophobia. The 
associated headache may be severe, requiring hospitalization for pain control; associated gastrointestinal 
symptoms, such as nausea, vomiting and diarrhea, may result in dehydration, exacerbating head pain 
and systemic symptoms [15]. WNM is generally associated with a favorable outcome, though, similar 
to WNF, some patients experience persistent headache, fatigue and myalgias [3,15].  
Cerebrospinal fluid (CSF) examination is characterized by a modest pleocytosis (elevation of white 
blood cells), generally less than 500 cells/mm3. While this pleocytosis is usually lymphocytic, which is 
typical of viral meningitis, CSF obtained soon after the onset of symptoms may show a neutrophilic 
predominance [17,18]. The presence of plasma cells has been suggested to be indicative of WN virus 
infection [19]; however, this finding requires further substantiation. 
2.2.2. West Nile Encephalitis (WNE) 
WNE may range in severity from a mild, self-limited confusional state to severe encephalopathy, 
coma and death. This manifestation is more commonly seen in older individuals, particularly over the 
age of 55, as well as immunocompromised persons [20,21]. Several neurological syndromes, primarily 
extrapyramidal disorders, have been observed in patients with WNE [3,5,6,22] and, in the setting of 
known virus circulation, may be very suggestive of WNV as the etiological agent for the encephalitis [3]. 
Patients with WNE frequently develop a coarse bilateral tremor, particularly in the upper extremities. 
The tremor tends to be postural and may have a kinetic component [3,4,6,22]. Myoclonus, predominantly 
of the upper extremities and facial muscles, may occur and may be present during sleep. Features of 
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parkinsonism, including hypomimia, bradykinesia and postural instability, may be seen and can be 
associated with falls and functional difficulties [3,23]. Cerebellar ataxia, with associated truncal instability 
and gait disturbance, leading to falls, has been described [6,22,24]. These abnormal movements usually 
follow the onset of mental status changes. Typically, these movement disorders resolve over time; 
however, tremor and parkinsonism may persist in patients recovering from severe encephalitis [3,5].  
The development of these movement disorders in WNE is due to specific neurotropism of WNV for 
extrapyramidal structures; there is frequent involvement of the brainstem (particularly, the medulla and 
pons), the deep gray matter nuclei, particularly the substantia nigra of the basal ganglia and the thalami, 
and the cerebellum [25–27]. This clinico-pathologic correlation may be extended to the neuroimaging 
abnormalities seen in West Nile encephalitis.  
The estimated proportion of patients with WNE who demonstrate abnormal findings in brain 
magnetic resonance imaging (MRI) varies considerably between studies; however, MRI findings are 
not ubiquitous, and even in cases of severe WNE, the MRI may be normal; or abnormal findings may 
not be apparent until several weeks after the onset of illness [28–30]. The most characteristic MRI 
findings in patients with WNE are bilateral signal abnormalities in the basal ganglia and thalami on 
T2- , fluid-attenuated inversion recovery (FLAIR) and diffusion-weighted image sequences, indicating 
the viral neurotropism for these deep gray structures (Figure 2). These MRI findings, which may be 
seen in other flaviviral encephalitides, including encephalitis, due to Japanese encephalitis virus and 
St. Louis encephalitis virus, may be indicative, but not diagnostic for, WNE. Electroencephalographic 
(EEG) abnormalities may be present in the form of generalized slowing, frequently anteriorly or 
temporally predominant, and triphasic sharp waves [31,32]. These EEG abnormalities, however, are 
also nonspecific. Overt seizures appear to be relatively uncommon with WNE and are estimated to 
occur in 3%–6% of patients [33]. Similarly, increased intracranial pressure and cerebral edema appear 
to be uncommon in WNE. CSF abnormalities in patients with WNE are essentially the same as those 
seen in WNM, characterized by moderate lymphocytic pleocytosis, elevated protein and normal 
glucose. One large study suggested that the mean CSF white blood cell count in patients with WNE was 
227 cells/mm3 (median, 90 cells/mm3) [34]. 
Figure 2. Fluid-attenuated inversion recovery magnetic resonance imaging sequence of the 
brain in a patient with West Nile virus encephalitis with associated parkinsonism and 
tremor, displaying signal abnormality in the substantia nigra (short arrow), the mesial 
temporal lobe (long arrow) and right posterior thalamus (thick arrow). 
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Neuropsychiatric symptoms, including depression, anxiety and apathy, have been reported among 
patients recovering from WNE [35,36]. Fatality rates from WNE have ranged from between 10% and 
30%, with mortality higher among older persons and immunocompromised individuals [1,2,37]. Of 
note, the severity of initial encephalitic illness does not necessarily predict ultimate outcome, as some 
individuals developing severe WNE have been observed to go on to have full recovery [3]. 
2.2.3. West Nile Poliomyelitis (WNP) and Other Forms of Acute Flaccid Paralysis (AFP) 
Acute and abrupt onset of limb weakness may be seen in WNV infection; in most cases, this limb 
paresis (partial weakness) or paralysis (complete loss of muscle power) is due to viral involvement of the 
lower motor neurons of the spinal cord (anterior horn cells), resulting in anterior (polio) myelitis [18,38–42]. 
This syndrome, typically associated with poliovirus, may be caused by a number of other viruses [43,44]. 
The clinical features of WNP are characteristic and generally dramatic, allowing for differentiation 
from the characteristic diffuse “muscle weakness” described by many persons with severe fatigue 
associated with WNV infection (Table 1). WNP generally develops soon after illness onset, usually 
within the first 24 to 48 h. Limb weakness generally develops rapidly and may be abrupt, occasionally 
raising clinical concern about stroke [45,46]. The weakness is usually asymmetric and often results in 
monoplegia (weakness of one limb). Patients with severe and extensive spinal cord involvement develop 
a more symmetric dense quadriplegia. Central facial weakness, frequently bilateral, can also be seen [38]. 
Sensory loss or numbness is generally absent, though some patients experience intense pain in the 
affected limbs just before or during the onset of weakness, and this limb pain may be persistent [18]. 
Table 1. Clinical and electrodiagnostic features of different types of weakness associated 
with West Nile virus infection. 
Characteristic 
West Nile 
Poliomyelitis 
Guillain–Barré Syndrome 
Fatigue-Related “Muscle 
Weakness” 
Timing of onset 
Acute phase of 
infection 
One to eight weeks 
following acute infection 
Acute infection 
Fever and 
leukocytosis 
Present Absent Present 
Weakness 
distribution 
Asymmetric; 
occasional monoplegia 
Generally symmetric; 
proximal and distal muscles 
Generalized, subjective, but 
neurologic examination normal 
Sensory symptoms 
Absence of numbness, 
paresthesias or  
sensory loss; pain often 
present 
Painful distal paresthesias 
and sensory loss 
Generally absent 
Bowel/bladder 
involvement 
Often present Rare Not present 
Concurrent 
encephalopathy 
Often present  Generally absent 
May be seen with fever, 
meningitis or encephalitis 
CSF Profile 
Pleocytosis and 
elevated protein 
No pleocytosis; elevated 
protein (albuminocytologic 
dissociation) 
Pleocytosis and elevated 
protein in the setting of 
meningitis/encephalitis 
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The most severe manifestation of WNP is the involvement of respiratory muscle innervation, 
leading to diaphragmatic and intercostal muscle paralysis and resulting in neuromuscular respiratory 
failure, requiring emergency endotracheal intubation [18,47]. Involvement of the lower brainstem, 
including the motor nuclei of the vagus and glossopharyngeal nerves, is similar to that seen in poliovirus 
infection and appears to be the underlying pathophysiologic basis for this manifestation [33,48]. 
Respiratory involvement in WNP is associated with high morbidity and mortality, and among 
survivors, prolonged ventilatory support lasting months may be required [18]; unfortunately, in some 
cases, patients are unable to be weaned from mechanical ventilation, and the withdrawal of ventilator 
support leads to death. Patients who develop bulbar findings, such as dysarthria, dysphagia or loss of 
gag reflex, are at greater risk for respiratory failure and should be monitored closely. 
Electrodiagnostic studies (electromyography/nerve conduction studies) will display findings consistent 
with a motor axonopathy with little or no demyelinating changes and preservation of sensory nerve 
potentials [49,50]. Spinal MRI may show signal abnormalities in the anterior spinal cord, consistent 
with anterior horn cell damage; ventral nerve root enhancement may be seen, as well (Figure 3). 
Other forms of AFP, including radiculopathy and the acute demyelinating polyradiculoneuropathy 
form of Guillain–Barré syndrome (GBS), have also been associated with WNV infection [51,52]. 
However, these syndromes appear to be far less common than poliomyelitis and may be differentiated 
on the basis of clinical and electrophysiologic features (Table 1). The weakness associated with GBS is 
usually symmetric, ascending (e.g., beginning in the legs and subsequently involving the arms and 
cranial nerve innervated muscles) and is associated with sensory and autonomic dysfunction. 
Additionally, CSF examination will generally show elevated protein in the absence of pleocytosis 
(‘cytoalbuminologic dissociation’), and electrodiagnostic studies may be consistent with a 
predominantly demyelinating polyneuropathy or prominent axonal damage (in the motor axonal 
variant of GBS). 
Figure 3. Sagittal (A) and axial (B) T2-weighted magnetic resonance imaging of the 
cervical spinal cord of a patient with bilateral upper extremity paralysis and respiratory 
failure from West Nile poliomyelitis, displaying the increased signal in the anterior spinal 
cord (circle and arrow). 
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Recovery of limb strength in persons with WNP is variable [18,53]. However, persistent weakness 
and associated functional disability appears to be the rule, at least in the short term; prolonged physical 
and occupational therapy may be required. Most limb strength recovery occurs within the first  
6–8 months after acute illness, following which improvement appears to plateau [53,54]. In particular, 
quadriplegia and respiratory failure are associated with high morbidity and mortality, and recovery is 
slow and incomplete [18]. More than 50% of the mortality associated with WNP occurs in patients 
with acute neuromuscular respiratory failure; of patients who survive respiratory failure due to WNP, a 
substantial number require prolonged tracheostomy or long-term supplemental oxygen [18,54]. In 
general, less profound initial weakness may be associated with more rapid and more complete strength 
recovery [18]. However, even patients with initially severe and profound paralysis may experience 
substantial recovery [18,53]; thus, as in encephalitis, the initial severity of paralysis is not necessarily a 
prognosticator of eventual outcome. This recovery phenomenon may in part be due to the involvement of a 
large number of motor neurons, which may initially be reversibly damaged, but are able to recover [42]. 
In addition, patients with WNP may be able, over time, to compensate for their motor deficits through 
the adaptation of motor skills, leading to improved functional recovery [55]. Electrodiagnostic studies 
may be useful in predicting the recovery of muscle strength, with subsequent improvement correlating 
with motor unit number estimate (MUNE) values [42]. Although case reports have suggested the 
occurrence of relapsing or delayed-onset cases of WNP [56], the long-term clinical and functional 
outcomes in patients with WNP is still emerging, and whether there may be the subsequent development 
of a delayed, “post-polio”-like syndrome years after acute illness is unknown. Subsequent prospective 
long-term evaluations of patients suffering from WNP will ultimately address this important question. 
3. Other Clinical Manifestations of West Nile Virus Infection 
3.1. Ocular Manifestations 
Ocular manifestations, including chorioretinitis and vitritis, are the most commonly reported clinical 
manifestation of WNV infection after fever and neuroinvasive disease [57–62]. The optic nerve and 
retina are essentially extensions of the CNS, but will be considered ocular manifestations in this review. 
Chorioretinal lesions associated with WNV infection have been described as multifocal and with a 
“target-like” appearance [58]; retinal hemorrhages have also been noted. Lesions tend to be clustered 
primarily in the temporal and nasal regions of the periphery of the fundus. This distribution and 
appearance of the chorioretinal lesions have been suggested to be distinctive for WNV infection [57]. 
One study in Tunisia identified chorioretinitis in 20 (69%) of 29 patients with laboratory-confirmed, 
symptomatic WNV infection [63]; the authors concluded that ophthalmoscopic examination should be 
performed on all patients with suspected WNV disease.  
An inflammatory vitritis has occurred concomitantly with the chorioretinitis and may be significant 
enough to obscure the optic disc. Symptomatic persons describe gradual visual blurring and loss, floaters 
and flashes. Although experience with management is limited, improvement both in symptoms  
and in underlying chorioretinal lesions has been observed following treatment with intraocular 
corticosteroids [58]. Occasional cases of optic neuritis (inflammation of the optic nerve) have been 
described in the setting of WNV infection [64]). To date, WNV has not been isolated intra-orbitally. 
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3.2. Other Miscellaneous Manifestations 
Numerous other clinical manifestations have been described in association with WNV infection; 
generally, these manifestations have been described in case reports or small case series, and a definitive 
causal association with WNV infection is difficult to substantiate. Rhabdomyolysis has been temporally 
associated with WNV infection [38,45], suggesting a viral myositis, but the presence of virus in 
muscle tissue has not been observed. Hepatitis and pancreatitis have been reported in cases of severe 
WNV infection [65,66], and WNV has been identified in hepatic and pancreatic specimens at 
pathology, suggesting that viscerotropic WNV disease may be an infrequent manifestation of infection. 
Myocarditis has been seen pathologically in WNV infection, and cardiac arrhythmias have occurred in 
persons with WNP, suspected to be due to autonomic dysfunction [67]. 
A study published in 2010 identified WNV RNA in the urine of five (20%) of 25 patients at up to 
seven years following acute WNV illness [68]. Four of the patients reported persistent subjective 
symptoms, and one patient had developed renal failure after their acute WNV illness. However, one 
subsequent study found no evidence of WNV RNA in urine samples collected from 40 patients  
at 6.5 years after acute WNV illness, and another study detected WNV RNA in the urine of only one 
(1.6%) of 63 persons tested <5 months after initial acute WNV infection [69,70]. The frequency of the 
persistence of WNV RNA in urine is unknown, and the clinical implications, if any, require  
further substantiation.  
4. West Nile Virus Long-Term Clinical and Functional Outcomes  
As the clinical experience with WNV infection has extended over a period of years, our understanding 
of the short- and long-term outcomes of WNV infection has grown. However, detailed data regarding 
these long-term neurologic and functional outcomes of WNV is still relatively sparse. As with other 
viral encephalitides, initial severe neurologic illness does not necessarily correlate with eventual outcome, 
and some patients with initial severe encephalopathy with associated coma may experience good 
recovery and minimal sequelae [3]. However, others experience persistent neurologic dysfunction, 
including movement disorders, headaches, fatigue and cognitive complaints. Large hospital-based 
series suggest that patients with severe WNE frequently require assistance with daily activities 
following acute care discharge [4,5]. Patients frequently report functional and cognitive difficulties for 
over a year following acute infection, and only 37% of patients in the 1999 New York City outbreak 
achieved full recovery at one year [71]. Of 265 persons developing symptomatic WNV infection in 
Idaho between 2006 and 2008, 53% reported one or more persistent symptom six months or more 
following acute illness; the most frequent complaints were fatigue, muscle aches and difficulties with 
memory and concentration [72]. Cognitive complaints, including difficulties with attention and 
concentration, have been described among patients recovering from WNE and suggest a subcortical 
type of cognitive dysfunction based on prominent thalamic and basal ganglia involvement [3]. 
However, limited formal and objective neuropsychometric assessments have been performed. A few 
studies have shown that persons recovering from WNV illness demonstrate measurable neurocognitive 
deficits on standardized testing as long as one year after acute illness [73,74]. Other studies, however, 
have shown that persons recovering from WNV illness do not perform significantly differently on 
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standardized neurocognitive assessments based upon the nature of clinical illness (e.g., WNF 
compared to WNM or WNE) or in comparison to unaffected persons [15]. However, self-reported 
fatigue, somatic and cognitive complaints are common among persons recovering from WNV illness, 
and subjective complaints and poorer performance on self-reported functionality indices have been 
seen in patients months or years following acute illness [71,75]. One study has suggested the 
normalization of self-reported symptoms within one year of acute illness [76]. As previously noted, 
neuropsychiatric symptoms, including depression and severe anxiety, have been reported by patients 
recovering from WNE [3,35,77].  
5. West Nile Virus Infection in Children 
Most children with symptomatic WNV infection present with WNF; of those who develop 
neuroinvasive disease, it most frequently manifests as meningitis [78–80]. However, severe and fatal 
encephalitis [81], poliomyelitis [82,83], rhombencephalitis [84] and hepatitis [85] have all been 
described in children with WNV infection. Similar to adults, immunocompromised children may be 
more susceptible to more severe illness [21].  
6. Risk Factors for Severe West Nile Virus Illness and Death 
Of all infected persons, less than 1% develop West Nile virus neuroinvasive disease (WNND). 
Although WNND has been reported among all ages, the proportion of persons who progress to WNND 
is greater among older compared to younger persons [8]. Serologic surveys in Romania and New York 
City indicate that WNV infection incidence is constant across all age groups during outbreaks [86,87], 
although serosurvey data are limited. Surveillance data from the United States indicate that age is the 
most important host risk factor for the development of WNND after infection. The incidence of 
neuroinvasive disease increases approximately 1.5-fold for each decade of life, resulting in a risk 
approximately 30 times greater for persons 80–90 years old compared to children younger than  
10 years old [8]. During outbreaks, hospitalized persons older than 70 years of age had case fatality rates 
of 15% in Romania [86] and 29% in Israel [88]. Encephalitis with severe muscle weakness and change 
in the level of consciousness were also prominent clinical risk factors predicting fatal outcome [88,89].  
Based upon a limited number of cases, patients who acquire WNV infection from infected donor 
organs are likely at a higher risk for severe neurologic disease and death compared with patients 
infected through the natural route of mosquito bite inoculation [90,91]. The risk of severe neurologic 
disease among other organ transplant recipients is not well-defined and may be related to the interval 
between infection and transplantation or the type of post-transplant immunosuppressive therapy. A 
seroprevalence study carried out in a Canadian outpatient transplant clinic following a WNV epidemic 
in 2002 indicated that the risk of neuroinvasive disease following infection was 40% (95% confidence 
interval 16%–80%) [92]. During that epidemic, transplant patients were approximately 40 times more 
likely than the general population to develop WNND [93]. However, a subsequent study assessed 
seropositivity and incidence of WNND among 194 solid organ transplant recipients and 195 controls 
and found no significant difference in seropositivity for WNV IgG between the groups and determined 
that the incidence of WNND among the transplant recipients was low among the seropositive 
transplant patients [94]. 
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In addition to increased age and organ transplantation, hypertension, cerebrovascular disease, renal 
disease and diabetes have also been identified as possible risk factors for WNND, and prior 
immunosuppression has been associated with a fatal outcome [88,89,95–99]. The incidence of 
neuroinvasive disease and the probability of death after acquiring neuroinvasive disease are slightly 
higher in men than in women [8].  
7. Treatment and Management 
There is currently no definitive treatment for WNV infection. Prevention of infection through 
protection from mosquito bites is therefore critical and the single most important public health 
measure. In the absence of definitive antiviral treatment, management of illness due to WNV infection 
remains supportive. Patients with otherwise uncomplicated WNF generally do not require specific 
intervention, though control of headache and rehydration may sometimes be needed. However, persons 
with documented WN viremia and patients with WNF in which other risk factors, including older age 
and underlying immunosuppression, are present should be observed for progression to more severe 
neuroinvasive disease. Patients with severe WNM may also require pain control for severe headache, 
and dehydration due to associated nausea and vomiting may require hospitalization for rehydration. In 
patients with WNE, attention to the level of alertness and airway protection is important. While 
seizures and increased intracranial pressure have been infrequently reported with WNE, if present, 
they should be managed appropriately.  
Patients with WNP may not have concurrent meningitis or encephalitis, and thus, WNV infection 
may not initially be suspected. This may result in the implementation of inappropriate diagnostic 
procedures or treatment modalities, including anticoagulation for suspected acute stroke or muscle 
biopsy for suspected myopathy. WNV infection should be suspected in persons developing acute 
asymmetric paralysis, particularly if accompanied by other signs of infection. Patients developing early 
dysarthria and dysphagia are at a higher risk for subsequent acute respiratory failure [18]; for this 
reason, hospitalization and observation of patients with poliomyelitis is prudent, and the development 
of dysarthria and dysphagia should be viewed with concern. Management of poliomyelitis due to 
poliovirus suggests that the initiation of aggressive physical activity during the acute febrile period of 
illness is associated with more profound and persistent weakness [100]; in the absence of additional 
data, the avoidance of aggressive physical activity during the acute febrile illness or during the initial  
48–72 h of weakness in WNP would be a reasonable approach, with subsequent application of physical 
and occupational therapy. 
Viremia in humans is short-lived, and WNV is usually cleared from the system by the time of 
clinical presentation; this fact presents a substantial theoretical obstacle for the targeting and design of 
specific anti-viral therapies. The recent use of several therapeutic modalities, including antiviral agents, 
nucleic acid analogues, missense sequences, immunomodulating agents and angiotensin-receptor blockers, 
has been outside the setting of carefully controlled, randomized, blinded, placebo-controlled trials; 
thus, anecdotal reports of the effectiveness of these agents are unsubstantiated. However, such anecdotal 
reports of effectiveness and the clinical desire to provide an intervention have led to empiric use.  
The immunomodulating agent, interferon-α, while again showing in vitro inhibition of cytotoxicity 
due to WNV [101], has not been fully evaluated in animal models, and data from an open-label,  
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non-blinded trial in the United States have not suggested a clear benefit. The use of interferon-α in the 
treatment of the closely related Japanese encephalitis virus suggested no benefit [102]. 
Animal models and anecdotal reports have suggested the efficacy of high-titer WNV-specific 
intravenous immune globulin (IVIG) from pooled donors (Omr-IgG-am®) [103–105], and humanized 
monoclonal WNV antibodies targeting the envelope protein of the virus (MGAWN1) [106–109]. 
However, animal models suggest that efficacy is greatest if these therapeutics are given prior to or very 
shortly after the onset of clinical illness, and attempts at human randomized clinical trials to assess the 
efficacy of these therapeutic agents have been unsuccessful, largely due to the challenge of enrolling a 
sufficient number of subjects within a likely therapeutic window. Neither of these products is licensed 
or available for use in the United States. As a result, the prevention of initial infection is the most 
critical component of any approach for the management of WNV illness.  
8. Conclusions 
Over the past decade, the understanding of the clinical spectrum of illness, as well as the immediate 
and longer-term outcomes associated with human WNV infection has increased substantially. 
However, there are remaining clinical questions that require further elucidation. Data on the long-term 
neurocognitive impact on patients recovering from WNE are scant, and further information is needed 
to ascertain long-lasting cognitive impairment following encephalitis from WNV. The parkinsonian 
features associated with acute WNV illness appear in most cases to be transient and resolve over time; 
however, recurrent- or early-onset parkinsonism in such patients due to the senescence of dopaminergic 
neurons remains a hypothetical possibility. Similarly, whether patients recovering from WNP will 
develop recurrent limb weakness in previously affected limbs years after their acute illness, akin to 
‘post-polio syndrome’ seen with poliovirus, is unknown at this point, but needs assessment. In the 
future, additional assessment of these and other clinical manifestations of WNV infection will be 
critical in aiding our understanding of the pathogenesis of WNV disease and hopefully will guide 
management and treatment options.  
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